ROARABLE
FREE $100K
Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / PRFX / financials
DCOY (31) HCWB (23) APVO (35) JUNS (29) ⌘ Pro Terminal β†’

PRF Technologies Ltd. (PRFX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$0.73 -2.68% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.73

PRF Technologies Ltd. (PRFX) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $2.6M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PRFX Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is PRFX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, PRF Technologies Ltd. (NASDAQ: PRFX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $0.73 (-2.68% 1D, market cap $2.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PRFX ranks #707 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does PRFX compare to DCOY and HCWB in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRFX carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, DCOY (Decoy Therapeutics Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $2.6M) and HCWB (HCW Biologics Inc.) posts a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $2.5M). Among the 5-stock peer group, PRFX leads on earnings multiple (N/A) while PRFX leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PRFX?
β–Ό

Per PRFX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001801834), PRF Technologies Ltd. generated $17.0K in revenue (-100.0% YoY), -$5.0M in net income, and -$4.0M in free cash flow against $12.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.73 (-0.67%)🧬 Dilution Drag (+1.28% YoY Shares)βš™οΈ Cash Engine: 8/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (33/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510033
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E Β· Rk D-
Cash (8)Whales (6)SEC (8)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-11% Base Target
$8 Bull$1 Base$1 Bear
πŸ“¬ FREE PRFX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for PRFX)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (33/100 Composite)
πŸ” WHY PRFX SCORES 33/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 0% Gross Margin

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 3/9

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
41
Grade D$0.82-11% Next Q
Q2 (-2Q)
38
Grade E$0.73+4.1% Next Q
Q3 (-1Q)
36
Grade E$0.76-3.9% Next Q
Current
33
Grade E$0.73-8.9% Hist 90D Ξ±
Trajectory: D (41) β†’ E (33)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a PRFX Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While PRFX currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.88) and Max Pain ($0.77) forces dealer call-delta covering toward $8.35.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PRFXβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œPRFX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 33%NO 67%Trade / Inspect Odds β†’
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL β€’ FY 2025 (10-K)

How PRFX Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)
Revenue$1.0MGross Profit $0 (0%)Cost of Sales $1.0MOp Profit $0 (0%)OpEx (R&D/SG&A) $0Net Profit$0 (0%)Tax/Other $0

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

β–  Revenueβ–  Net Profitβ–  Free Cash Flow
FY23
Rev $26.8M
FY24
Rev $41.1M
FY25
Rev $17.0K
Fiscal YearRevenueGross MarginOp MarginNet ProfitFree Cash FlowROIC %
FY 2025$17.0K-50%-80%-$5.0M-$4.0M-45%
FY 2024$41.1M8%-35.7%-$14.6M-$12.6M-45%
FY 2023$26.8M8%-35.7%-$9.3M-$6.7M-35%
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRFX)

  • βœ“Walkthrough of PRFX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
PRFX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -62.94%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-03O $0.75H $0.75L $0.73C $0.73VOL 58.6K
RES: $1.25SUP: $0.64SMA50: $0.88SMA200: $1.79
$5.72$4.36$2.99$1.63$0.27RES $1.25SUP $0.64$0.732026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PRFX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ PRFX Butterfly Map β†’ + Track PRFX β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -100.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PRFX today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for PRFX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PRFX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRFX)

Health Care Rank #707 of 1015 βš”οΈ DCOY vs PRFX Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (PRFX vs. DCOY, HCWB, APVO, JUNS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, PRF Technologies Ltd. (PRFX) ranks #707 by composite RQD confidence (33/100, grade E) and #981 by equity capitalization ($2.6M). Within this direct 5-issuer industry benchmark cohort, PRFX leads on earnings valuation at N/A trailing P/E, while PRFX leads on capital efficiency and profitability with -35.0% ROIC and -30.0% gross margin. APVO currently holds the highest overall quantitative score in the immediate peer group at 35/100 (D-) compared with PRFX at 33/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PRFX ACTIVE
PRF Technologies Ltd.
E 33/100 β€” -30.0% -35.0% -2.68% $2.6M Benchmark Subject
DCOY
Decoy Therapeutics Inc.
E 31/100 β€” β€” -35.0% -13.01% $2.6M /dcoy-vs-prfx β†’
HCWB
HCW Biologics Inc.
E 23/100 β€” 20.0% -35.0% -6.78% $2.5M /hcwb-vs-prfx β†’
APVO
Aptevo Therapeutics Inc.
D- 35/100 β€” β€” -35.0% -1.47% $2.4M /apvo-vs-prfx β†’
JUNS
Jupiter Neurosciences Inc.
E 29/100 β€” 80.6% -35.0% -13.50% $2.7M /juns-vs-prfx β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001801834 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), PRF Technologies Ltd. (PRFX) reported GAAP revenue of $17.0K (-100.0% vs. FY2024 revenue of $41.1M , and -99.9% cumulative change since FY2023) , GAAP net income of -$5.0M, operating cash flow of -$4.0M, and free cash flow of -$4.0M (+68.7% YoY). On the balance sheet, PRFX closed FY2025 with $12.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $17.0K -$5.0M -$4.0M -$4.0M $12.0M β€”
FY2024 (FY) 2024-12-31 $41.1M -$14.6M -$12.6M -$12.6M $4.5M β€”
FY2023 (FY) 2023-12-31 $26.8M -$9.3M -$6.7M -$6.7M β€” β€”

3. PRFX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PRFX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, PRF Technologies Ltd. (NASDAQ: PRFX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $0.73 (-2.68% 1D, market cap $2.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, PRFX ranks #707 in composite RQD confidence.

How does PRFX compare to DCOY and HCWB in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRFX carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, DCOY (Decoy Therapeutics Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $2.6M) and HCWB (HCW Biologics Inc.) posts a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $2.5M). Among the 5-stock peer group, PRFX leads on earnings multiple (N/A) while PRFX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PRFX?

Per PRFX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001801834), PRF Technologies Ltd. generated $17.0K in revenue (-100.0% YoY), -$5.0M in net income, and -$4.0M in free cash flow against $12.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PRFX trading relative to its 50-day, 200-day, and 52-week technical levels?

PRFX last traded at $0.73 (-2.68% on volume of 58,596 shares), positioning the stock -17.05% below its 50-day simple moving average ($0.88) and -59.22% below its 200-day simple moving average ($1.79). Across its 52-week range of $0.69 to $7.95, PRFX sits at the 0.6% percentile with a 14-day RSI of 37.9 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($1.00 to $0.82).

Direct Sub-Reports: PRFX RQD Cockpit PRFX 12M Forecast PRFX Earnings & Move PRFX Dividends & DRIP PRFX Insiders & 13F PRFX Whale Options PRFX Profit Sankey PRFX News & Why
ROARABLE RATING BRIEF β€’ RQD 33/100 (E) βœ“ SEC XBRL & RQD VERIFIED

PRFX β€” PRF Technologies Ltd.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

PRF Technologies Ltd. (PRFX) earns a live Roarable RQD composite score of 33/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.73 (-2.68% 1D, market capitalization $2.6M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of -30.0%, operating margin of -60.0%, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

PRF Technologies Ltd. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry,. The source data identifies the company's product and customer base only through its news items, which reference an OcuRingβ„’-K trial and a GridFeedβ„’ strategy for AI data center power, but does not describe revenue sources or customers. Revenue is reported as β€” in each annual period.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), PRF Technologies Ltd. (PRFX) reported $17.0K in annual revenue (up from $41.1M in FY2024, -100.0% YoY) and -$5.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($26.8M revenue, -$9.3M net income) through FY2025, PRFX scaled operating cash flow to -$4.0M and free cash flow to -$4.0M, backed by $12.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 33/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 6/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $0.69 – $7.95 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), PRFX carries a macro regime beta of 1.00 and gross margin of -30.0%.

  • Key Question #1: Can PRFX sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $17.0K and free cash flow of -$4.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is PRFX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PRFX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for PRF Technologies Ltd. (PRFX) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to PRFX Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PRFX Bull vs. Bear Conversation Board β€” What's Your Call at $0.73?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PRFX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PRFX:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER β€’ Options Flow Specialist πŸ‚ BULLISH 🎯 Target: $0.96 (+31.5%)
πŸ“Œ Pinned Debate

Reported cash of $11 million in news headlines, plus a Phase 2 trial plan, could support runway if the figure is confirmed.

Long PRFX at $0.73 targeting $0.96. Reported cash of $11 million in news headlines, plus a Phase 2 trial plan, could support runway if the figure is confirmed.. Institutional whale score is 6/20 and the risk/reward vs. the $0.69 52-week low is skewed heavily in favor of bulls.

RetailWhale_TX πŸ‚ BULL

Both sides have a point here β€” PRFX's 8/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FO ForensicBear RQD DEBATE OPENER β€’ 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $0.62 (-15.1%)
Spot @ $0.73

ROIC of -35%, zero revenue in each reported period, and an E-grade RQD score of 34 indicate severe forensic and cash-generation risk.

Fading this rally in PRFX at $0.73. ROIC of -35%, zero revenue in each reported period, and an E-grade RQD score of 34 indicate severe forensic and cash-generation risk.. With a beta of 1.0 and the stock sitting at $0.73 (52-wk range $0.69–$7.95), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%